Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Gastrin is a target of the β-catenin/TCF-4 growth-signaling pathway in a model of intestinal polyposis
Theodore J. Koh, … , Andrea Varro, Timothy C. Wang
Theodore J. Koh, … , Andrea Varro, Timothy C. Wang
Published August 15, 2000
Citation Information: J Clin Invest. 2000;106(4):533-539. https://doi.org/10.1172/JCI9476.
View: Text | PDF
Article

Gastrin is a target of the β-catenin/TCF-4 growth-signaling pathway in a model of intestinal polyposis

  • Text
  • PDF
Abstract

Mutations in the adenomatous polyposis coli (APC) tumor suppressor gene occur in most colorectal cancers and lead to activation of β-catenin. Whereas several downstream targets of β-catenin have been identified (c-myc, cyclin D1, PPARδ), the precise functional significance of many of these targets has not been examined directly using genetic approaches. Previous studies have shown that the gene encoding the hormone gastrin is activated during colon cancer progression and the less-processed forms of gastrin are important colonic trophic factors. We show here that the gastrin gene is a downstream target of the β-catenin/TCF-4 signaling pathway and that cotransfection of a constitutively active β-catenin expression construct causes a threefold increase in gastrin promoter activity. APCmin–/+ mice overexpressing one of the alternatively processed forms of gastrin, glycine-extended gastrin, show a significant increase in polyp number. Gastrin-deficient APCmin–/+ mice, conversely, showed a marked decrease in polyp number and a significantly decreased polyp proliferation rate. Activation of gastrin by β-catenin may therefore represent an early event in colorectal tumorigenesis and may contribute significantly toward neoplastic progression. The identification of gastrin as a functionally relevant downstream target of the β-catenin signaling pathway provides a new target for therapeutic modalities in the treatment of colorectal cancer.

Authors

Theodore J. Koh, Clemens J. Bulitta, John V. Fleming, Graham J. Dockray, Andrea Varro, Timothy C. Wang

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Gastrin is a downstream target of the APC/β-catenin pathway. (a) Schemat...
Gastrin is a downstream target of the APC/β-catenin pathway. (a) Schematic representation of a 1,300-bp human gastrin promoter construct (19) containing several potential TCF-4–binding sites. TCF-4–binding sites with high homology to the known TCF/Lef-HMG box transcription factor consensus motifs [CC(A/T)TTG(A/T)(A/T)(T/C); ref. 25, 27] were identified in the gastrin promoter using Lasergene99 DNA-analysis software. Homologous bases are printed as capital letters: –1166 tCTTTGgca-1156, –1000 GATGAAACC-990, –822 aCTTTGTcT-812, –516 CCATTGcTC –506, –103 CCATTccTC-93. (b) Northern blot analysis of RNA taken from HT-29-APC and HT-29-GAL cells that were induced with zinc to express either wild-type APC or β-galactosidase. The blot was probed with either a riboprobe to human gastrin exon 2 or GAPDH. (c) HeLa cells were transfected with a series of gastrin promoter-luciferase reporter deletion constructs (number reflects length of promoter from the transcriptional start site) and then cotransfected with a constitutively active β-catenin expression construct alone (filled bars) or with both the constitutively active β-catenin expression construct with a dominant-negative TCF-4 construct (open bars). The basal promoter construct Pxp2 was used as a control. The results are taken from three independent experiments. (d) Sequences containing either the wild-type TCF-4–binding site from –103 to –90 on the gastrin promoter, a mutated TCF-4–binding site, or a corresponding perfect TCF-4 consensus sequence (Con) are shown. These sequences were used to generate heterologous promoter constructs by cloning them upstream of the thymidine kinase promoter in the luciferase reporter construct pT81. (e) HeLa cells were then transfected with the wild-type TCF-4-pT81 construct, the mutant TCF-4-pT81 construct, the consensus TCF-4-pT81 construct, or an empty pT81 construct and a constitutively active β-catenin expression construct (filled bars) or both the constitutively active β-catenin expression construct and a dominant-negative TCF-4 construct (open bars).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts